Malaysia already classifies etomidate as Group B poison amid rising misuse concerns in Singapore, says health minister
He explained that any future policy decisions will be made based on evidence rather than public alarm.
'Regarding the side effects of etomidate reported in Singapore, I'm fully aware of the case. The product in question is already listed under Group B poisons in Malaysia.
'It is considered an active substance used in clinical practice. It's not an issue of classification, as it is already categorised appropriately,' he said in a press conference after officiating the National Health Technology Assessment Conference 2025.
Dzulkefly said there is no controversy surrounding etomidate's use or classification in Malaysia.
He added that while the government is open to reviewing any proposals concerning the substance, all decisions will be guided by rigorous, evidence-based evaluation rather than isolated incidents.
'I don't wish to comment further on the matter, even in cases involving death and so on; we do not base our decisions on such incidents alone.
'Our decision-making process remains grounded in what is actually substantiated, guided by a rigorous, evidence-based approach. I have no objections to reviewing the matter, but our approach will always prioritise scientific evidence and clinical standards,' he said.
On July 20, Singapore Health Minister Ong Ye Kung announced plans to classify etomidate as a Class C substance under the Misuse of Drugs Act, citing growing concern over the rise in vaping products laced with the anaesthetic, CNN reported.
He said the trend has alarmed key agencies, including the Health Ministry and the Ministry of Home Affairs due to its potential health and safety risks.
On Friday, The Straits Times reported that Singapore's Health Sciences Authority (HSA) confirmed etomidate was found in the blood samples of two individuals involved in a fatal road accident on Punggol Road in May.
Police had recovered 42 e-vaporisers and over 1,200 pods from the vehicle, with tests by HSA confirming that some of the products contained the drug.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Free Malaysia Today
3 hours ago
- Free Malaysia Today
No MySejahtera data leak, says Dzulkefly
Health minister Dzulkefly Ahmad denied claims that there was a data breach involving 3.2 million MySejahtera users in April. PETALING JAYA : The health ministry has denied claims of a data breach involving 3.2 million MySejahtera users in April, saying no such incident took place. Health minister Dzulkefly Ahmad said checks with the relevant agencies found no evidence of any leak involving personal data on MySejahtera as alleged. 'There was no data breach involving 3.2 million MySejahtera users in April,' he said in a written parliamentary reply. Dzulkefly said the health ministry remained committed to protecting data integrity and strengthening cybersecurity measures. This includes full compliance with a government circular which outlines protocols for managing cybersecurity incidents in the public sector. He was responding to Azman Nasrudin (PN-Padang Serai), who asked about the status of the Malaysian Communications and Multimedia Commission's investigations into the alleged data leak.
New Straits Times
4 hours ago
- New Straits Times
Sexual transmission accounts for 96pct of new HIV cases in Malaysia
KUALA LUMPUR: Sexual transmission now accounts for nearly all new HIV cases in Malaysia, marking a significant shift from previous patterns of infection through needle sharing, the Dewan Rakyat was told. Health Minister Datuk Seri Dr Dzulkefly Ahmad said that in 2024, 96 per cent of new HIV infections were linked to sexual contact, with 64 per cent involving homosexual or bisexual transmission and 32 per cent through heterosexual transmission. "In 2024, a total of 3,185 new HIV cases were reported, with a notification rate of 9.4 per 100,000 population. "The majority of cases were among men, accounting for 90 per cent, compared to 10 per cent among women. "This trend marks a shift from the 1990s, when women made up only 1 per cent of cases and men 99 per cent," he said in a written parliamentary reply published today. He was responding to Tan Kok Wai (PH-Cheras), who enquired about the current status of HIV infections in the country, including the number of patients by age group and gender, as well as the main causes of transmission. Dzulkefly said 75 per cent of the cases reported last year involved youths aged between 20 and 39. "New HIV or AIDS infections in Malaysia generally recorded a 50 per cent decline between 2000 and 2009. "However, from 2010 until now, the rate of decline has slowed, registering only a 27 per cent reduction." In February, Dzulkefly said more than 60 per cent of HIV infections last year were transmitted through homosexual and bisexual relations. He said a key factor behind this increase in transmission is the inconsistent use of condoms, especially among high-risk groups.
The Star
7 hours ago
- The Star
Hepatitis C treatment can be safely shortened
A new clinical trial conducted in Malaysia has found that an eight-week regimen of ravidasvir and sofosbuvir is just as safe and effective as the standard 12-week treatment for chronic hepatitis C. This finding could accelerate efforts to scale up access to treatment in resource-limited settings by reducing treatment duration, costs and system burden. The EASE study (Evaluating Accelerated Shortened treatment for hepatitis C in Asia through real-world Evidence) was led by the Health Ministry (MOH) and conducted across 26 sites nationwide between March 2021 and March 2023. The randomised trial involved 322 patients diagnosed with chronic hepatitis C virus infection, including those with more complex medical profiles. The primary objective was to determine whether an eight-week treatment course using the fixed-dose combination of ravidasvir and sofosbuvir would achieve similar sustained virological response (SVR), compared to the standard 12-week regimen. An SVR refers to the continued absence of the hepatitis C virus in a patient's blood 12 weeks or more after they have completed treatment. It is essentially considered a virological cure for the infection. The study found no significant difference in efficacy between the two durations, with high SVR rates maintained in both arms. Safety profiles were also comparable, with no new adverse effects identified. The results were officially reported by the MOH in January (2025) and presented at the 2025 European Association for the Study of the Liver (EASL) Congress in early May in Amsterdam, the Netherlands. Ravidasvir was co-developed through a public-health partnership involving the MOH, Drugs for Neglected Diseases initiative (DNDi), Pharco Pharmaceuticals (Egypt) and Pharmaniaga Berhad (Malaysia), with key clinical trials conducted in Malaysia and Thailand. The treatment was first registered in Malaysia in 2021 and added to the World Health Organization (WHO) Essential Medicines List in 2023. While hepatitis C continues to affect approximately 50 million people globally, with only about 20% receiving treatment, high drug prices remain a barrier in many countries. A 2023 MOH study estimates 0.4% of the population in Malaysia to have hepatitis C. In line with WHO targets, Malaysia aims to eliminate the disease as a public health threat by 2030.
